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ABSTRACT: Type III collagen (Col3) has been proposed to play a key role in tissue repair based upon its temporospatial expression
during the healing process of many tissues, including bone. Given our previous finding that Col3 regulates the quality of cutaneous
repair, as well as our recent data supporting its role in regulating osteoblast differentiation and trabecular bone quantity, we
hypothesized that mice with diminished Col3 expression would exhibit altered long-bone fracture healing. To determine the role of Col3
in bone repair, young adult wild-type (Col3þ/þ) and haploinsufficent (Col3þ/) mice underwent bilateral tibial fractures. Healing was
assessed 7, 14, 21, and 28 days following fracture utilizing microcomputed tomography (microCT), immunohistochemistry, and
histomorphometry. MicroCT analysis revealed a small but significant increase in bone volume fraction in Col3þ/ mice at day 21.
However, histological analysis revealed that Col3þ/ mice have less bone within the callus at days 21 and 28, which is consistent with
the established role for Col3 in osteogenesis. Finally, a reduction in fracture callus osteoclastic activity in Col3þ/ mice suggests Col3
also modulates callus remodeling. Although Col3 haploinsufficiency affected biological aspects of bone repair, it did not affect the regain
of mechanical function in the young mice that were evaluated in this study. These findings provide evidence for a modulatory role for
Col3 in fracture repair and support further investigations into its role in impaired bone healing.  2015 Orthopaedic Research Society.
Published by Wiley Periodicals, Inc. J Orthop Res 33:675–684, 2015.
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Regenerative medicine seeks to restore function to
damaged tissues. Approximately 1.5million bone graft
procedures are performed in the United States each
year in an attempt to improve problematic skeletal
healing, with an overall annual global economic bur-
den valued at over $1 billion.1,2 Despite the use of
such procedures, as well as advances in synthetic
biomaterials and biological therapeutics, fracture com-
plications in trauma patients remain a formidable
clinical problem. The resulting morbidity and health-
care expenditure underscores the need to develop
novel treatments. Research that elucidates critical
biological components of adjunctive therapies, includ-
ing “smarter” biomaterials, is clearly needed.
Type III collagen (Col3) is a homotrimeric fibril-
forming collagen found in many connective tissues.
Col3 expression is increased during development as
well as early in the healing process of a variety of
tissues such as bone, tendon, ligament, and skin.3–5
Fracture callus has been shown to contain consider-
able amounts of Col3, which is later replaced by type 1
collagen (Col1).6–8 However, the role of Col3 in tissue
repair has remained enigmatic. Until recently, the
only known role of Col3 in tissue homeostasis involved
regulation of type I collagen (Col1) fibrillogenesis.9
Our laboratory has recently shown that Col3 plays an
important role in cutaneous wound repair, that is,
distinct from type I collagen in its ability to promote a
regenerative response and limit scar formation.10
Specifically, Col3 deficiency results in increased scar
deposition by promoting differentiation of myofibro-
blasts, the key cells that influence pathologic scarring.
Furthermore, we have recently shown that Col3
regulates osteoblastogenesis and the quantity of tra-
becular bone.11 In addition to its expression in the
early fracture callus,4,12 several lines of evidence
support a role for Col3 in repair and maintenance of
bone, including its requirement for growth accelera-
tion of osteoblasts,13 its potential role in preserving
osteogenic potential of mesenchymal stem cells,14 and
its ability to increase angiogenesis.15
A critical role for Col3 in both maintenance and
repair of tissues and organs, including the skeleton, is
equally apparent in human clinical medicine. Patients
with vascular Ehlers–Danlos syndrome (EDS), who have
mutations or deficiency in Col3, have structural failure
and poor repair of cardiovascular, gastrointestinal, and
urogenital tissues.16,17 Although death in vascular EDS
patients is most often associated with catastrophic
failure of these soft tissue structures, patients also have
been reported to display numerous skeletal abnormali-
ties including a distinctive facial appearance, spinal
deformity, scoliosis, club foot, temporal mandibular
disorder, and osteoporosis.18–20 Although poor repair of
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affected soft tissue organs in vascular EDS patients is
well documented, it is unknown if diminished Col3 has
significant effects on repair of the skeletal system,
including long bone fracture. Notably, Col3 levels decline
with age, and low levels are also associated with
diabetes, smoking, certain medications (i.e. steroids),
and the post-menopausal state21–27—all risk factors for
poor bone healing.
Given the data supporting a critical role for Col3 in
tissue repair and regeneration and its role in skeletal
development and maintenance, we investigated the
hypothesis that diminished Col3 would negatively
impact fracture repair through its effects on progenitor
and reparative cell function and recruitment to sites
of injury. Because of the potential clinical relevance of
diminished rather than absent Col3, the poor survival
of Col3-null mice (<5% beyond weaning9,11), and the
current lack of availability of conditional Col3 trans-
genic mice, fracture repair was assessed in Col3 wild-
type, and haploinsufficient littermates. Previously,
Col3 haploinsufficient mice were found to express half
the amount of Col3 in tissues compared to wild-type
littermates.9,28,29 Our recent work confirmed that Col3
expression in long bones of Col3þ/ mice is approxi-
mately half of that seen in Col3þ/þ mice.11 In this
study, using a bilateral closed, transverse tibial frac-
ture mouse model, we show that diminished Col3 leads
to decreased bone formation and alterations in remod-
eling during fracture healing. These findings suggest
that Col3 may play an important role during fracture
healing and support further studies to determine the
impact of a complete absence of Col3 on fracture repair
and under circumstances in which fracture repair
would be delayed such as in aged individuals or those
with ischemic injury.
METHODS
Experimental Design
Animal utilization and care was approved by the Institutional
Animal Care and Use Committee (IACUC) of the University
of Pennsylvania and followed guidelines set forth in the
National Institutes of Health Guide for the Care and Use of
Laboratory Animals. To determine expression of Col3 tempo-
rally during fracture repair in this tibial fracture model,
mRNA that had been characterized previously for markers of
bone healing30 was used to quantify gene expression of Col3
and Col1 at 2, 5, 10, and 20 days post fracture (dpf; n¼ 4–5)
using quantitative real-time polymerase chain reaction
(QPCR). Then to investigate the effect of diminished Col3 on
the process of fracture repair, bilateral tibial fractures were
performed on 12–16 week old female Col3 wild-type (þ/þ)
mice and Col3 deficient (þ/) littermates. Specimens were
harvested at 7, 14, 21, and 28 days post-fracture (dpf).
MicroCT analysis using a vivaCT 40 MicroCT system (Scanco
Medical, Switzerland) was performed to evaluate bone and
callus volume. After microCT, tibiae were prepared for
histology and immunohistochemistry/fluorescence. Specifical-
ly, immune-localization for Col3, Safranin-O staining to
analyze cartilage, immunohistochemistry for proliferating cell
nuclear antigen (PCNA) to identify cellular proliferation and
tartrate resistant acid phosphatase (TRAP) staining to assess
osteoclastic activity were performed using histologic sections
of fractures. Finally, a comparison of fracture biomechanics
between the two genotypes was performed by torsion testing.
QPCR
Temporal expression of Col3 in fracture repair was assessed
using previously generated cDNA isolated from fractures
spanning the time frame examined in this study.31 Briefly,
gene expression was quantified from cDNA of mRNA purified
from day 2, 5, 10, and 20 fracture calluses (n¼ 4 or 5 per
time point) using a 7500 Fast Real-Time PCR system
(Applied Biosystems, Life Technologies, Grand Island, NY)
from a total of 10ml of Master Mix per well, which included
1 Fast SYBR Green (Applied Biosystems), 0.5ml of cDNA,
and previously described forward and reverse primers
(0.45mM) for Col1, Col3, and GAPDH.11 For each gene of
interest, samples were run in triplicate and results analyzed
as previously described.
Production and Genotyping of Col3-Deficient Mice
All mice for this study were generated in a colony established
at the University of Pennsylvania from breeder pairs of
Col3A1 heterozygous (Col3þ/–) mice originally purchased from
Jackson Laboratories (Bar Harbor, ME). These mice had been
generated by homologous recombination by replacement of the
promoter region and first exon of the Col3 gene with a 1.8-kb
PGKneo cassette.9 Animals were genotyped for Col3 by PCR
analysis of DNA extracted from tail biopsies as described
previously.11 At the time of genotyping, mice were micro-
chipped for identification (Allflex FDX-B transponders; Allflex
USA, Inc., Dallas, TX). All mice were identified based upon the
last four digits of the implanted microchip to maintain blinding
of genotype during analysis, as previously described.10
Tibial Fracture Procedure
Closed, transverse, mid-diaphyseal bilateral tibial fractures
were created similar to previously published methods.32
Briefly, under isoflurane anesthesia, a small incision was
made medial to the tibial tuberosity. The bone cortex was
punctured using a 26-gauge needle, and a 0.009-inch sterile
diameter rod was inserted through the length of the intra-
medullary canal. The incision was closed with surgical glue
(GLUture; Abbott Laboratories, Abbott Park, IL). Fractures
were created using a custom made three-point bending
apparatus. Buprenorphine (0.05mg/kg) was administered
subcutaneously prior to and twice daily for 3 days after
surgery for analgesia.
Tissue Harvest and Preparation
All mice were euthanized via CO2 inhalation. Fractured
tibiae were carefully dissected and fixed in 4% paraformalde-
hyde (PFA) at 4˚C for 24–48h. The intramedullary pins were
then removed and tibiae were transferred to 70% ethanol
until further processing for microCT. After microCT, the legs
were decalcified in 15% formic acid for 14h, then were
dehydrated in ethanol and embedded in paraffin as previous-
ly described.30 Sagittal sections (8mm) through the block
were prepared for histology and immunofluorescence (IF)
and immunohistochemistry (IHC).
IF and IHC
For Col3 immunolocalization studies, sections of fractured
tibias (7, 14, and 28 dpf) were mounted on positively charged
slides (Fisher Scientific, Pittsburgh, PA) that were treated
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with VectaBond (Vector Laboratories Inc., Burlingame, CA)
to ensure bone adherence to the slides. After heating at 60˚C
overnight, sections were deparaffinized in xylene and rehy-
drated through ethanols to water. Antigen retrieval was
carried out using pepsin (Worthington Biomedical Corpora-
tion, Lakewood, NJ, 1mg/ml, 37˚C, 1h, 0.01N HCl).33 Slides
were blocked in 5% BSA and exposed to a Col3 primary
antibody (ab7778; Abcam, Cambridge, MA) for 72h at 4˚C.
After incubation with the primary antibody, slides were
washed and exposed to secondary antibody Alexa Fluor 488
goat anti-rabbit F(ab’)2 fragment (Invitrogen, Grand Island,
NY) at 1:500 for 30min at 37˚C, washed and stained with 4,6-
diamidino-2-phenylindole (DAPI; Vector Laboratories Inc.).
Sections incubated without primary antibody served as nega-
tive controls. Qualitative 100 and 200 images were taken
on a Leica DM RBE fluorescent microscope equipped with a
Q-Imaging Retiga 2000 CCD camera (QImaging Surry, BC,
Canada) controlled by iVision software (Biovision, Exton, PA).
For peroxide-based immunohistochemistry, sections of the
fractured tibia at 7, 14, or 21 dpf (4–5 samples per group)
were deparaffinized, rehydrated and immersed in heated
sodium citrate buffer. Slides were blocked and exposed to the
primary antibody of PCNA (Abcam). After treatment with the
primary antibody (PCNA, 1:1,000), sections underwent perox-
idase blocking with 3% H2O2 and were then treated with
biotin-conjugated secondary antibody at 1:200 (Santa Cruz
Biotechnology, Santa Cruz, CA). After secondary antibody
treatment, slides were incubated with streptavidin-conjugat-
ed horseradish peroxidase (HRP; Abcam) and then with 3,30-
diaminobenzidine (DAB) as the chromogen. Slides were
counterstained with Gill’s hematoxylin, dehydrated, mounted
using Permount (Biomeda, Foster City, CA) and visualized
using an Olympus BX51 light microscope and Spot RT3
camera. Negative controls were sections with no primary
antibody staining. Skin sections served as positive controls.
Safranin-O Histology
Safranin-O staining was performed to determine the total
cartilage area within the fracture callus. Briefly, slides of the
fractured left tibia were deparaffinized, rehydrated, stained
with hematoxylin, rinsed in dH20, exposed to 0.3% Fast
Green FCF, rinsed in 1% acetic acid, immersed in 0.1%
Safranin-O, rinsed in dH2O, dehydrated and mounted. These
samples were used for measuring total cartilage area within
the fracture callus, as described previously.30
Histomorphometry
As previously described,30 Safranin-O positive area of the
callus was measured at 20 magnification using MetaMorph
Image Analysis software (Molecular Devices, Sunnyvale, CA).
Contours of the fracture callus were manually defined and
then color threshold was applied to identify areas of Safra-
nin-O positive staining within the callus. The thresholded
area was divided into total area to calculate the percentage.
For quantification of PCNA, two to three areas of undiffer-
entiated mesenchyme adjacent to the fracture callus per
sample were captured using a 40 objective (400) and were
analyzed using ImageJ software (National Institutes of
Health, Bethesda, MD [http://rsb.info.nih.gov/ij/]), as previous-
ly described.30 High resolution TIF images were imported into
ImageJ, and then the Color Deconvolution plugin (http://
www.dentistry.bham.ac.uk/landinig/software/cdeconv/cdeconv.
html) was applied to differentiate positive (brown) from nega-
tive (blue) cells. Thresholding was applied to separate positive
and negative cells into discrete images, and then the “Analyze
Particles” command was executed to count the cells. The
percent of positive cells was determined by comparing
the number of positive cells to the total number of cells. The
average between samples was taken and standard error was
computed.
Assessment of Osteoclast Numbers
Osteoclasts were identified by positive staining for TRAP
activity using the Acid Phosphatase, Leukocyte (TRAP) kit
(Sigma, St Louis, MI), following the manufacturer’s instruc-
tions. Histologic sections from PFA fixed, paraffin embedded
samples (day 21 and 28) described above were utilized
(Col3þ/þ n¼ 4 dpf 21, n¼ 7 dpf 28) and Col3þ/ (n¼ 5 dpf
21, n¼ 6 dpf 28). Paraffin was removed with xylene, and
sections were rehydrated in decreasing concentrations of
ethanol. For each sample, osteoclasts were counted in three
non-overlapping 200 fields within the callus and the bone
surface perimeter was traced and quantified using ImageJ.
Woven Bone Histology Measurements
Histologic sections were processed and stained with hema-
toxylin and eosin (H&E) as described.18 (Col3þ/þ mice: n¼ 4
dpf 21, n¼ 7 dpf 28; Col3þ/ mice: n¼ 5 dpf 21, n¼ 6 dpf 28).
One 200 brightfield image was taken for each fracture,
capturing the entire callus. Using ImageJ, bone was selected
based on a color threshold. The cortical bone was not
included in the analysis, and the perimeter (bone surface) of
the remaining woven bone was measured.
Micro-Computed Tomography
Tibiae were wrapped in 70% ethanol-soaked gauze and
scanned using a vivaCT 40 MicroCT system (Scanco Medical)
with an isotropic 3D voxel size of 21mm. A semi-automated
contouring method was used to determine the callus perimeter.
Briefly, callus and cortical bone sections were manually
identified on the first slice and then had spline interpolation
between points. The points were chosen on slices no more than
ten slices apart (0.105mm). These points were manually
reviewed across every slice and re-interpolation was performed
if necessary. The cortical bone sections were removed from the
image, and a global threshold was applied that calculated bone
volume, tissue mineral density, bone mineral density, callus
(tissue) volume, bone volume fraction, bone mineral content
and tissue mineral content. Any comminuted fracture, or
fracture not located mid-shaft, was excluded from analysis.30
Biomechanical Testing
A randomly assigned subset of the fractured tibiae was
tested in torsion, as previously described.34 These fractures
had been fixed and stored as described above. Prior to
biomechanical testing, bones were rehydrated in PBS for 3 h
as previously described.35 Whole bone specimens were potted
using a low-melting temperature bismuth alloy (Cerrobend,
Cerro Products, Bellefont, PA), mounted in a torsion mechan-
ical testing system (Bose ElectroForce 3300, Bose Corpora-
tion, Eden Prairie, MN), and tested in external rotation at
0.3˚/s until failure. Using a MATLAB script, raw data were
filtered and stiffness, angular displacement at failure, torque
at failure, and energy to failure were measured.
Statistical Analysis
Values are expressed as mean standard error of the mean
(SEM) in the text and figures, unless otherwise stated.
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Normality was determined using the Shapiro–Wilk test.
Unpaired student’s t-tests or the Wilcoxon Rank Sum test
was utilized to determine statistical significance between two
groups of normally distributed or non-normally distributed
data, respectively. When multiple comparisons were per-
formed, significance between groups was assessed by one
way analysis of variance (ANOVA), followed by a Tukey’s
posthoc test, or a 2-way ANOVA followed by a Bonferroni
posthoc test to determine significance between groups.
Unadjusted p-values less than or equal to the critical level
set by the posthoc test after multiple comparisons were made
were considered significant. Study groups were compared
utilizing SigmaPlot software (Systat Inc., Chicago, IL).
p-values <0.05 were considered statistically significant.
RESULTS
Col3 Expression is Increased During Fracture Repair
To determine the expression pattern of Col3 during
fracture repair in our closed tibial fracture model, we
performed QPCR using samples that had previously
been characterized for chondrogenic and osteogenic
marker expression.31 Consistent with previous reports
of an increase in Col3 expression during the early
repair process of a variety of tissues, including bone,
an increase in Col3 was evident by day two post-
fracture. Col3 expression was significantly elevated
starting at day 5 (p<0.05) and up to 20 days post-
fracture compared to non-injured bone (Fig. 1A). Simi-
lar to previous reports, an increase in expression of
type I collagen (Col1) lags behind that of Col3 with
significant (p< 0.01) elevation over baseline levels not
occurring until day 20 post-fracture.36 To assess
distribution of Col3 in the fracture callus, we per-
formed immunoflourescent localization in day 7, 14,
and 28 fractures. Consistent with previous publica-
tions examining bone Col3 expression in other spe-
cies,6–8,37–39 we found that minimal to no Col3
expression could be found in mature (uninjured) corti-
cal bone, although Col3 expression could be detected
in trabeculae and was found to be highly expressed
within the periosteum (Fig. 1B). Within the early
fracture callus (day 7; Fig. 1C), Col3 was found within
the undifferentiated mesenchyme and to a lesser
extent in the cartilage. At later stages of healing, Col3
can be visualized in the walls of newly formed vessels,
as well as trabeculae (days 14 and 28; Fig. 1D and E).
By comparison, Col3 expression was diminished within
the cartilage where it can be visualized surrounding
only a subset of chondrocytes at day 14 (Fig. 1D),
similar to previous reports in the rabbit and rat.6,7 In
the newly formed bone of day 28 fractures, Col3
containing fibers were found in the immature woven
bone but were absent in more mature lamellar bone,
suggesting Col3 is replaced as remodeling progresses
and returns to a steady state level (Fig. 1E).
Callus Cartilage Volume Is Not Significantly Affected by
Col3 Levels During Fracture Healing
Since Col3 is elevated early during the fracture
healing process, coincident with cartilage formation,
we next investigated whether endochondral ossifica-
tion was altered with Col3 deficiency. At day 14 and
21 after fracture, there was no significant difference
seen in percent cartilage composition of the callus
between Col3 haploinsufficient and wild-type mice
(Fig. 2), although there was a trend for Col3 haploin-
sufficient mice to have increased cartilage at day 14
(50% increase). This could indicate a delay in endo-
chondral ossification, or may be reflective of more
cartilage forming in the callus of Col3þ/ mice
relative to that in wild-type mice. By day 21, calluses
from both groups of mice had formed a boney union
and contained little to no detectable cartilage.
MicroCT Analysis of Tibial Fracture in Young Adult
Col3þ/þ and Col3þ/ Mice
Given our previous findings that Col3 deficiency nega-
tively impacts osteogenesis in vitro and trabecular bone
quantity in vivo, we next examined the amount of bone
that forms in the callus. Surprisingly, mCT analysis
showed that, overall, there were few significant differ-
ences in the bone that forms in the callus of Col3þ/
and Col3þ/þ mice at 14, 21, or 28 days after fracture
(Fig. 3). However, bone volume fraction (bone volume/
total callus volume) and bone mineral density were
significantly higher in Col3þ/ mice compared to
Col3þ/þ littermates at day 21 post-fracture (Fig. 3C
and D). This finding was likely due to the smaller callus
volume seen in Col3þ/ mice (although not significant)
at this time point (Fig. 3A), suggesting that the Col3
haploinsufficient mice exhibit altered fracture healing
dynamics. By day 28, however, tissue (callus) volume
was decreased in both groups with enhanced Bone
Mineral Densities, consistent with callus maturation
between day 21 and 28 (Fig. 3A, C, and D), suggesting
remodeling at this time between both groups of mice.
The Content of Bone Within the Fracture Callus Is
Significantly Reduced in Col3þ/ Mice
Interestingly, histologic examination of calluses from
21-day-old fractures suggested that Col3þ/ mice had
a reduction in the amount of bone present within the
callus compared to Col3þ/þ mice. Quantitative analy-
sis of total bone surface within the callus confirmed
that Col3þ/ mice had significantly less bone surface
compared to wild-type mice (Fig. 4). This difference
was most pronounced at day 21, but continues through
day 28 fractures. It is notable that histological bone
surface (Fig. 4) decreased from days 21 to 28 in both
the Col3þ/þ and Col3þ/ mice, consistent with the
decrease in bone volume observed with microCT
(Fig. 3B). It should be noted that no significant differ-
ences were found in biomechanical properties between
fractured tibia (day 28) of the two genotypes in torsion
testing (Supplemental Table S1).
Mesenchymal Cell proliferation Within the Fracture Callus
Is Not Significantly Different Between Col3þ/ and
Col3þ/þ Mice
To further characterize whether the discrepancy in bone
surface area in Col3þ/ and Col3þ/þ mice was the
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Figure 1. Col3 expression is upregulated by day 2 after fracture and remains elevated until at least day 28 after fracture.
Quantitative real-time RT-PCR was performed on fractured tibia of mice on C57Bl/6 background (n¼ 4 or 5 per group) for Col1 and
Col3 expression. Results are presented as the fold-change of mRNA normalized to GAPDH (meanSD), which was used as the
endogenous control. Col3 is significantly higher than base line (0 day post fracture) at days 5 and 20 post-fracture (p<0.05), while
significant elevation in Col1 above base line did not occur until day 20 (##p<0.01). (B–E) Bone H&E and Col3 immunofluorescent
staining to show Col3 localization during fracture healing. Green, Col3; Red, bone autofluorescence; Blue, DAPI. Scale bars¼ 200mm.
(B) 10 and 20 images of uninjured bone. 20 field of view is boxed in 10 image. (C–E) Whole tibia, 10 and 20 images of day 7
(C), 14 (D), and 28 (E) post fracture callus. 10 field of view is boxed in whole tibia image, and 20 field of view is boxed in 10 image.
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Figure 2. Histological analysis of fracture calluses does not show differences in cartilage composition during healing. (A) Safranin-O
staining in tibial fractures in wildtype and Col3 haploinsufficient mice (days 14 and 21 post fracture), revealing the presence of
proteoglycan (arrows). By day 21, there is little to no cartilage present in the fracture callus. Scale bar¼ 400mm. (B) Quantification of
percent cartilage found in fracture callus day 14 and 21 after fracture (n¼4 or 5).
Figure 3. MicroCT analysis of tibial fracture in young adult Col3þ/þ and Col3þ/ mice. Microcomputed tomography analysis
demonstrates significant differences in bone volume fraction and bone mineral density at 21 days post fracture in Col3 wild-type
(Col3þ/þ; black bars) and Col3 haploinsufficient (Col3þ/; gray bars) mice. (A) Quantification of total callus volume (TV), (B) bone
volume (BV), (C) bone volume relative to total callus volume (bone volume fraction; BV/TV), (D) bone mineral density (BMD),
(E) (callus) mineral density (TMD), (F) bone mineral content (BMC), and (G) tissue (callus) mineral content (TMC) at day 14, 21,
and 28 after tibial fracture (n¼8–10 per group). p< 0.05.
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result of altered cellular proliferation in the fracture
callus, we compared PCNA staining in the fracture
calluses of Col3þ/ and Col3þ/þ mice. Undifferentiated
mesenchyme of the developing fracture callus showed
that proliferation differences (% PCNA-positive staining)
were not significantly different between the two geno-
types at either day 7 or 14 after fracture (Fig. 5A and B).
At day 21, there was a small but insignificant increase
in proliferation of cells around the bone perimeter in
calluses of Col3þ/ mice compared to wild-type mice.
Osteoclast Activity Is Attenuated in the Fracture Callus of
Col3þ/ Mice Compared to Wild-Type Mice
Because our data suggested alterations in early callus
remodeling between the two genotypes, we evaluated
osteoclast number using TRAP histochemistry at
days 21 and 28 (Fig. 6). Results indicated very low
numbers of osteoclasts per bone surface in the Col3þ/
mice at day 21, significantly less than that that found
in wild-type mice (p<0.001). By day 28, however, there
was no significant difference between the wild-type
and Col3 deficient mice with respect to osteoclast
number, although the density of osteoclasts increased
significantly in the fracture callus of Col3 mice from
day 21 to 28.
DISCUSSION
Col3 has been proposed to play a role in tissue repair
and regeneration due to the early increase in its
expression following tissue injury; however, its specific
Figure 4. Col3-deficient fractures contain less bone. (A) Representative H&E images of Col3þ/þ and þ/ fractures 28 dpf. (B) Bone
selected and shown in black. (C) The perimeter of the bone within the callus was selected. (D) High magnification images of
these fractures show a reduction in the amount of bone in Col3þ/ calluses. Scale bar¼ 250mm for all images. (E) Quantification of C.
Col3þ/ fractures have significantly less bone surface within the callus than Colþ/þ fractures, p<0.05.
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role in fracture repair has not been elucidated. Consis-
tent with previous reports citing induction of Col3
expression in the early stages of healing of a variety of
tissues,3–5 our results show that Col3 mRNA levels
begin to increase within the first 2 days following long
bone fracture and remain significantly elevated over
the first 3 weeks. Our data further shows that Col3 is
found throughout the undifferentiated mesenchyme,
within blood vessels and immature woven bone of the
murine fracture callus, similar to its previously de-
scribed distribution in other species.6–8,37–39 Col3 is
present but diminished, by comparison, within the
cartilaginous matrix. Based upon in situ hydridization
studies by Bland et al.,8 it is likely Col3 in the
cartilaginous matrix is a remnant from the pre-existing
fibrous matrix laid down by mesenchymal progenitors.
This expression pattern suggests that Col3 may modu-
late undifferentiated mesenchymal and osteogenic cell
activity and fate during fracture healing, and is in line
with its previously defined role in osteoblast differenti-
ation and trabecular bone formation and maintenance.
Furthermore, this data also suggests that Col3 is less
likely to play a significant role in endochondral ossifi-
cation,6 which is further supported by the fact that
long bone length is similar between Col3þ/þ and
Col3þ/ mice.11
As many risk factors associated with poor fracture
healing, such as age, smoking, corticosteroid adminis-
tration, and diabetes, have also been associated with
reductions in tissue Col3 expression,21–27 we examined
the hypothesis that fracture repair would be delayed
in mice that are haploinsufficient for Col3 compared to
wild-type mice. We have previously shown that bone
Figure 5. Nuclear proliferation of undifferentiated mesenchyme does not differ between Collagen 3 deficient mice and wild-type
mice during fracture healing. (A) Histological sections (40) of undifferentiated mesenchyme (UDM) around the callus at day 7, 14,
and bone (21 days) after fracture show positive PCNA staining (black nuclei). (B) Percent of proliferating cells for both wild-type and
Col3þ/ mice shows no significant difference in the undifferentiated mesenchyme at either day 7 or day 14 after fracture (n¼4–6). (C)
Quantification of PCNA positive (proliferating) cells divided by all cells in the bone perimeter for both wild-type and Col3þ/ mice
shows no significant difference at day 21 after fracture (n¼4–6). Scale bars¼25mm.
Figure 6. Osteoclast numbers are reduced in Col3þ/ com-
pared to Col3þ/þ calluses 21 days post fracture. Osteoclasts
within the callus 21 and 28 days post fracture (dpf) were
identified by TRAP staining. Osteoclast number was normalized
to bone surface for quantification. Osteoclast numbers per mm
bone surface were significantly reduced in Col3þ/ mice dpf 21
when compared to Col3þ/þ, and osteoclasts decreased between
21 and 28 dpf for Col3þ/þ mice, but increased in Col3þ/
fractures, p<0.05 and p<0.001 via 1-way ANOVA followed
by a Tukey post hoc test (n.s., not significant).
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Col3 mRNA levels of young adult Col3þ/ mice are
approximately half of that seen in Col3þ/þ mice.11
Our results suggest that a reduction in bone Col3 in
young adult mice does not prevent or significantly
delay fracture repair, although significant differences
do exist in fracture healing between Col3þ/ mice and
their wild-type littermates. Bone volume (BV) and
tissue volume (TV) measured by microCT were not
significantly different between genotypes at day 21;
however, a disproportionate decrease in TV values
in Col3þ/ mice likely contributed to a significant
increase in bone fraction volume (BV/TV) seen in
Col3þ/ mice compared to Col3þ/þ mice at that time.
This was somewhat surprising given the significant
increase in BV/TV of uninjured bone in Col3þ/þ mice
compared to Col3þ/ littermates.11 More consistent
with the uninjured bone phenotype is the histologic
assessment of bone surface area in the fracture callus,
which shows a significant reduction in woven bone
within the fracture callus of Col3þ/ mice compared
to wild-type littermates at days 21 and 28 (Fig. 4).
Discrepancy between these two modalities have been
noted by others,40 prompting advocation for comple-
mentary analysis using both microCT and histomorph-
ometry. It is possible that the larger trabeculae seen
on histology were beneath the single threshold chosen
for microCT analysis in this study at the day 21 time
point. On the other hand, histological assessment of
bone does not set mineral inclusion thresholds for
analysis. A smaller but significant reduction in intra-
callus bone surface was still evident at day 28,
suggesting differences between the genotypes were
normalizing at that time. Given this normalization of
bone surface area and the similarity in bone fraction
volume between genotypes, as determined by microCT
analysis, it is not surprising that no significant differ-
ences were noted in biomechanical properties in
torsional testing at that time.
Given the apparent bimodal expression of Col3 in
the undifferentiated mesenchyme and later in the
immature bone of the fracture callus, we examined the
effect of Col3 haploinsufficiency on proliferation of
mesenchymal cells. No significant differences were
found in proliferation of undifferentiated mesenchyme
within the callus between the two genotypes at early
time points (day 7 and 14 post fracture), suggesting
that Col3 haploinsufficiency does not limit expansion
of progenitor cells. We also did not find significant
differences in proliferative capacity of cells within
newly formed bone of day 21 fractures. We have
previously shown that Col3 regulates osteoblastogene-
sis, and primarily affects trabecular bone development
via osteoblast differentiation, with Col3 deficient mice
having reduced osteogenesis and less trabecular
bone.11 These findings provide a potential mechanism
for the decrease in bone surface area associated with
Col3 deficiency (Fig. 4).
In addition, we also examined potential effects of
Col3 in modulating osteoclast activity within the
fracture callus. Interestingly, TRAP staining revealed
a significant reduction in osteoclast activity in the
fracture callus of Col3þ/ mice at day 21 (Fig. 5). We
propose that this transiently decreased osteoclastic
activity associated with Col3 deficiency (Fig. 6) is
coupled to diminished osteoblast activities at that
time11 and that this decreased osteoclastic response
leads to the normalization of early differences in new
bone formation between Col3þ/ and Col3þ/þ mice.
However, an alternative hypothesis is that Col3 may
directly modulate osteoclast activity. Collectively, our
data suggest that Col3 may play its most significant
role in the fracture callus through its ability to
modulate bone formation and coupled remodeling.
A possible limitation with this study that may
explain why a more profound impact of relative Col3
deficiency on fracture repair was not seen was the
age of the mice used. The efficiency of healing in
the young adult mice used in this study may not
have allowed for detection of the full spectrum
healing differences in Col3þ/ mice. Evidence sup-
porting this possibility include the fact that patients
with vascular EDS do not develop clinical symptoms
until the 3rd or 4th decade of life.16 Furthermore,
both cutaneous wound healing differences and vascu-
lar abnormalities are not evident in Col3þ/ mice
until at least middle age (>1 year).10 The exact
mechanism for the impact of age on Col3 phenotype
during healing is currently under investigation, but
may be due to additional modifications to the extra-
cellular matrix (ECM) associated with aging, changes
in compensatory factors with age, or may be associat-
ed with a further decline in Col3 that accompanies
aging23–25 which results in Col3 falling below a
critical level necessary to support efficient repair.
Although investigation of the impact of Col3 deficie-
ncy in an aged model of fracture repair is beyond the
scope of the current investigation, our data suggest-
ing that Col3 modulates the repair process in frac-
ture healing supports future investigation in an aged
model to determine a greater role for Col3 in this
population of individuals and identify the potential
for Col3-biomaterials to accelerate delayed healing in
geriatric patients.
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